No Data
Exelixis Analyst Ratings
Schrödinger To Present Phase 1 Clinical Data On MALT1 Inhibitor SGR-1505 At EHA Annual Congress And International Conference On Malignant Lymphoma
Needham Reiterates Hold on Fate Therapeuticsto Hold
Exelixis Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Sales Guidance With Its Midpoint Above Estimates. The Company, Acting as a Collaboration Partner of Invenra, Initiated the...
Fate Therapeutics Analyst Ratings
Invenra's Collaboration Partner Exelixis Initiates The Dose-Escalation Stage Of The First-In-Human Phase 1 Clinical Study Of XB628 In Participants With Recurrent Advanced Or Metastatic Solid Tumors